Central venous device‐related infection and thrombosis in patients treated with moderate dose continuous‐infusion interleukin‐2

Eastman, Michael; Khorsand, Masoud; Maki, Dennis G.; Williams, Eliot Churchill; Kim, KyungMann; Sondel, Paul M.; Schiller, Joan H.; Albertini, Mark R.

doi:10.1002/1097-0142(20010215)91:4<806::aid-cncr1068>3.3.co;2-b

Cited by 15 publications

(16 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our study, white‐cell growth factors were associated with VTE only in patients with cancers that had already predisposed to VTE (upper gastrointestinal, lung, and lymphoma). White‐cell growth factors are often prescribed in the setting of infection, a known risk factor for VTE,30, 47, 48 and this may have contributed to the increased frequency observed. However, we found no association between documented infection during chemotherapy and the subsequent occurrence of VTE in our study population.…”

Section: Discussionmentioning

confidence: 99%

Risk factors for chemotherapy‐associated venous thromboembolism in a prospective observational study

Khorana

Francis

Culakova

et al. 2005

Cancer

513

403

View full text Add to dashboard Cite

BACKGROUND The incidence of venous thromboembolism (VTE) is increased in cancer, but little information is available about risk factors in cancer patients on chemotherapy. METHODS We analyzed data from a prospective, multicenter observational study to determine the frequency and risk factors for VTE in ambulatory cancer patients initiating a new chemotherapy regimen. The association of VTE with clinical variables was characterized using univariate and multivariate analysis. RESULTS Among 3003 patients treated with at least one cycle of chemotherapy, VTE occurred in 58 (1.93%) over a median follow‐up of 2.4 months (0.8%/mo). The incidence varied significantly by site of cancer (P = 0.01) with highest rates in upper gastrointestinal (2.3%/mo) and lung cancer (1.2%/mo), and lymphoma (1.1%/mo). An elevated prechemotherapy platelet count was significantly associated with an increased rate of VTE (P for trend = 0.005). The incidence of VTE was 3.98% (1.66%/mo) for patients with a prechemotherapy platelet count ≥ 350,000, compared with 1.25% (0.52%/mo) for patients with platelet counts of < 200,000 (P for trend=0.0003). In multivariate analysis, a prechemotherapy platelet count of ≥ 350,000/mm3 (adjusted OR 2.81, 95% CI 1.63–4.93, P = 0.0002), site of cancer, hemoglobin < 10g/dL or use of erythropoietin, and use of white cell growth factors in high‐risk sites of cancer were significantly associated with VTE. CONCLUSIONS Symptomatic VTE is a frequent complication of chemotherapy. The prechemotherapy platelet count is a unique risk factor and can help identify high‐risk patients for future trials of thromboprophylaxis. Cancer 2005. © 2005 American Cancer Society.

show abstract

Section: Discussionmentioning

confidence: 99%

Risk factors for chemotherapy‐associated venous thromboembolism in a prospective observational study

Khorana

Francis

Culakova

et al. 2005

Cancer

513

403

View full text Add to dashboard Cite

show abstract

“…Interleukin-2, interleukin-6, interleukin-1b, and tumor necrosis factor-alpha have been reported elevated in patients with ABD (24). Interleukin-2 has been related with reduced peak diastolic filling rate at radionuclide ventriculography in patients with cancer (31) as well as with vascular thrombosis (32,33). Interleukin-6 has been found to initiate coagulation (34) and to cause myocardial dysfunction in experimental studies (35).…”

Section: Discussionmentioning

confidence: 99%

Aortic elastic properties and left ventricular diastolic function in patients with Adamantiades-Behcet's disease

Ikonomidis

Lekakis

Stamatelopoulos

et al. 2004

Journal of the American College of Cardiology

View full text Add to dashboard Cite

show abstract

“…The most common consequence of CRT is an increased risk of infection (Eastman et al , ). There appears to be a higher incidence of bacteraemia in patients with a line thrombosis (Raad et al , ) and this may be as a result of earlier bacterial colonization (predominantly cocci) that occurs once a fibrin sheath is formed.…”

Section: Consequences Of Thrombosismentioning

confidence: 99%

Catheter‐related thrombosis in cancer patients

2013

View full text Add to dashboard Cite

SummaryCentral venous catheters are commonly used in haematology departments for the administration of chemotherapy, blood products and parenteral nutrition in patients with haematological malignancy. Thrombosis is a recognized complication of such devices especially in oncology patients. Catheter-related thrombi (CRT) may lead to pulmonary embolism and infection, as well as catheter failure and potential delays in treatment. The vast majority of CRT are asymptomatic, thus a high index of suspicion is required in making the diagnosis. Doppler ultrasound or venography may be employed to identify CRT. Once confirmed, the initiation of treatment is a balance between the risks of anticoagulation against potential complications of CRT. A number of risk factors for CRT are discussed along with an overview of catheter types, their appropriate choice and intravascular positioning.

show abstract

Central venous device‐related infection and thrombosis in patients treated with moderate dose continuous‐infusion interleukin‐2

Cited by 15 publications

References 5 publications

Risk factors for chemotherapy‐associated venous thromboembolism in a prospective observational study

Risk factors for chemotherapy‐associated venous thromboembolism in a prospective observational study

Aortic elastic properties and left ventricular diastolic function in patients with Adamantiades-Behcet's disease

Catheter‐related thrombosis in cancer patients

Contact Info

Product

Resources

About